日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

CDK9 Inhibition by Dinaciclib Is a Therapeutic Vulnerability in Epithelioid Hemangioendothelioma

Dinaciclib 抑制 CDK9 是上皮样血管内皮瘤的治疗弱点

Ajaybabu V Pobbati, Ashley Burtscher, Nandini Rajaram Siva, Andrea Hallett, Todd Romigh, Kepeng Che, Bin Zhao, Jesse A Coker, Nancy Wang, Shaun R Stauffer, Brian P Rubin

Loss of CDKN2A Cooperates with WWTR1(TAZ)-CAMTA1 Gene Fusion to Promote Tumor Progression in Epithelioid Hemangioendothelioma

CDKN2A 缺失与 WWTR1(TAZ)-CAMTA1 基因融合协同促进上皮样血管内皮瘤肿瘤进展

Caleb N Seavey, Andrea Hallett, Shuo Li, Kepeng Che, Ajaybabu V Pobbati, Shuang Ma, Ashley Burtscher, Ryan Kanai, John M Lamar, Brian P Rubin

The TAZ-CAMTA1 Fusion Protein Promotes Tumorigenesis via Connective Tissue Growth Factor and Ras-MAPK Signaling in Epithelioid Hemangioendothelioma

TAZ-CAMTA1 融合蛋白通过结缔组织生长因子和 Ras-MAPK 信号传导促进上皮样血管内皮瘤中的肿瘤发生

Shuang Ma, Ryan Kanai, Ajaybabu V Pobbati, Shuo Li, Kepeng Che, Caleb N Seavey, Andrea Hallett, Ashley Burtscher, John M Lamar, Brian P Rubin

Aurintricarboxylic acid is a canonical disruptor of the TAZ-TEAD transcriptional complex

金精三羧酸是 TAZ-TEAD 转录复合物的典型干扰物

Kepeng Che, Ajaybabu V Pobbati, Caleb N Seavey, Yuriy Fedorov, Anton A Komar, Ashley Burtscher, Shuang Ma, Brian P Rubin

Inhibition of PI3K and MAPK pathways along with KIT inhibitors as a strategy to overcome drug resistance in gastrointestinal stromal tumors

抑制 PI3K 和 MAPK 通路以及使用 KIT 抑制剂作为克服胃肠道间质瘤耐药性的策略

Anu Gupta, Shuang Ma, Kepeng Che, Ajaybabu V Pobbati, Brian P Rubin